Skye Bioscience Class Action Lawsuit Filed Over Efficacy Claims
ByAinvest
Monday, Jan 19, 2026 2:28 am ET1min read
SKYE--
Investors who purchased Skye Bioscience shares between November 4, 2024 and October 3, 2025 may be eligible to participate in a class action lawsuit against the company. Skye allegedly made false and misleading statements about its nimacimab treatment, which failed to demonstrate the efficacy it had previously claimed. Shareholders who suffered a loss are encouraged to contact the DJS Law Group regarding possible lead plaintiff appointments. The deadline to participate is January 16, 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet